Why my Name: Venetoclax (ABT199) CAS#: 1257044-40-8 is so yellow.

Venetoclax (ABT199) CAS#: 1257044-40-8

 

Why my color is so yellow? Because HPLC more than 99%, Impurity is too less.

 

So my color is so beautiful.

 

Venetoclax (ABT199) CAS#: 1257044-40-8, 12 Intermediates, 15 Impurity.

 

All from GMP, ISO plant.

 

Batch size is more than 50kg.

 

Yellow is Quality.

Description: Venetoclax, also known as ABT-199 or GDC0199, is an orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.

Name: Venetoclax (ABT199) 

CAS#: 1257044-40-8 

Chemical Formula: C45H50ClN7O7S 

Exact Mass: 867.3181 

Molecular Weight: 868.44 

Elemental Analysis: C, 62.24; H, 5.80; Cl, 4.08; N, 11.29; O, 12.90; S, 3.69

2017 China CPHI: E1M35

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

労働時間: Beijing Time 4:00AM~11:00PM

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Skype: willgutian

QQ: 2393923585

REFERENCES

1: Seymour J. ABT-199 for Chronic Lymphocytic Leukemia. Clin Adv Hematol Oncol. 2014 Oct;12(10):698-700. PubMed PMID: 25658896.

2: Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015 Jan 15;6:e1593. doi: 10.1038/cddis.2014.525. PubMed PMID: 25590803.

3: Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4(Wild-type) and CXCR4(WHIM) mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jan 12. doi: 10.1111/bjh.13278. [Epub ahead of print] PubMed PMID: 25582069.

4: Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. Leuk Lymphoma. 2015 Jan 28:1-7. [Epub ahead of print] PubMed PMID: 25373508.

5: Ko TK, Chuah CT, Huang JW, Ng KP, Ong ST. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget. 2014 Oct 15;5(19):9033-8. PubMed PMID: 25333252; PubMed Central PMCID: PMC4253416.

6: Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9. PubMed PMID: 25301704.

7: Zhao X, Bodo J, Sun D, Durkin L, Lin J, Smith MR, Hsi ED. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015 Mar;168(5):765-8. doi: 10.1111/bjh.13149. Epub 2014 Oct 4. PubMed PMID: 25284608.

8: ABT-199 shows effectiveness in CLL. Cancer Discov. 2014 Sep;4(9):OF7. doi: 10.1158/2159-8290.CD-NB2014-102. Epub 2014 Jul 3. PubMed PMID: 25185206.

Biggest Manufacturer Glecaprevir (ABT-493), 1365970-03-1 and Intermediates.

Biggest Manufacturer Glecaprevir (ABT-493), 1365970-03-1 and Intermediates.

Glecaprevir (ABT-493), 1365970-03-1, hplc 98.5%, stock 10kg. NMR, HPLC 99%, LCMS is ok.

We are China biggest supplier.

The sample picture:

Glecaprevir Intermediates 1365970-48-4, hplc 98.5%, stock 100g. NMR, HPLC, LCMS is ok. 
Product name: (3 3 R,3 5 S,9 1 R,9 2 R,5S,E)-5-(tert-butyl)-14,14-difluoro-4,7-dioxo-2,8,10 - trioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopentanacyclotetradecaphan-12-ene-3 5 -carboxyl ic acid purity:98% CAS number : 1365970-48-4

Glecaprevir Intermediates 1365970-47-3,  hplc 98.5%, stock 100g. NMR, HPLC, LCMS is ok.
Product name: methyl(3 3 R,3 5 S,9 1 R,9 2 R,5S,E)-5-(tert-butyl)-14,14-difluoro-4,7- dioxo -2,8,10-trioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopentanacyclotetradecaphan-12-ene-3 5 -carboxylae purity:98% CAS number : 1365970-47-3 

Glecaprevir Intermediates 1360828-80-3,  hplc 98.5%, stock 100g. NMR, HPLC, LCMS is ok.
Product name:(1R,2R)-1-amino-2-(difluoromethyl)-N-((1-methylcyclopropyl)sulfonyl)cyclopropane-1-carboxamide hydrochloride purity:98% CAS number :1360828-80-3

Glecaprevir Intermediates 1294512-27-8,  hplc 98.5%, stock 100g. NMR, HPLC, LCMS is ok.
Product name: 2-chloro-3-(1,1-difluoroallyl)quinoxaline purity:98% CAS number : 1294512-27-8

Glecaprevir Intermediates 1365970-45-1, hplc 98.5%, stock 100g. NMR, HPLC, LCMS is ok.
 Product name:(S)-2-(((((1R,2R)-2-(allyloxy)cyclopentyl)oxy)carbonyl)amino)-3,3-dimethylbutanoic acid purity:98% CAS number : 1365970-45-1

017 China CPHI: E1M35

網址: www.eosmedchem.com 

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

Name: Glecaprevir 
CAS#: 1365970-03-1 
Chemical Formula: C38H46F4N6O9S 
Exact Mass: 838.2983 
Molecular Weight: 838.87 
Elemental Analysis: C, 54.41; H, 5.53; F, 9.06; N, 10.02; O, 17.16; S, 3.82

Synonym: ABT-493; A-1282576; ABT493; A1282576; ABT 493; A 1282576
IUPAC/Chemical Name: (33R,35S,91R,92R,5S,E)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-14,14-difluoro-4,7-dioxo-2,8,10-trioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopentanacyclotetradecaphan-12-ene-35-carboxamide
InChi Key: MLSQGNCUYAMAHD-ITNVBOSISA-N
InChi Code: InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
SMILES Code: O=C([C@H]1N(C2)C([C@H](C(C)(C)C)NC(O[C@@](CCC3)([H])[C@]3([H])OC/C=C/C(F)(F)C4=NC5=CC=CC=C5N=C4O[C@]2([H])C1)=O)=O)N[C@@]6(C(NS(=O)(C7(C)CC7)=O)=O)[C@H](C(F)F)C6

TECHNICAL DATA
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
Harmonized System Code: 293490

REFERENCES
1: Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment. Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081. [Epub ahead of print] PubMed PMID: 28128852.
2: Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016 Oct;151(4):651-659.e1. doi: 10.1053/j.gastro.2016.07.020. PubMed PMID: 27456384.
3: Lim SG. HCV management in resource-constrained countries. Hepatol Int. 2017 Feb 21. doi: 10.1007/s12072-017-9787-0. [Epub ahead of print] Review. PubMed PMID: 28224352.

NMR, HPLC 99%, LCMS, Cobimetinib(XL-518) , CAS: 934660-93-2, 12G in stock, Pls check:

NMR, HPLC, LCMS, COA, Pls kindly check:

Name: Cobimetinib 
CAS: 934660-93-2
Chemical Formula: C22H22F3IN2O2 
Exact Mass: 530.06781 
Molecular Weight: 530.32196 
Elemental Analysis: C, 49.83; H, 4.18; F, 10.75; I, 23.93; N, 5.28; O, 6.03
Related CAS #: 1369665-02-0 (fumarate)   934660-93-2 (free base)    
Synonym: XL518; XL 518; XL-518; GDC0973; GDC 0973; GDC-0973; cobimetinib.

TECHNICAL DATA
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

2017 China CPHI: E1M35

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

労働時間: Beijing Time 4:00AM~11:00PM

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Skype: willgutian

QQ: 2393923585

REFERENCES
1: Choo EF, Ng CM, Berry L, Belvin M, Lewin-Koh N, Merchant M, Salphati L. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemother Pharmacol. 2013 Jan;71(1):133-43. doi: 10.1007/s00280-012-1988-6. Epub 2012 Oct 7. PubMed PMID: 23053270.
2: Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N, Williams SP. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res. 2012 May 31;2(1):22. doi: 10.1186/2191-219X-2-22. PubMed PMID: 22651703; PubMed Central PMCID: PMC3405466.
3: Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, Kim AI, Koltun ES, Lougheed JC, Manalo JC, Martini JF, Nuss JM, Peto CJ, Tsang TH, Yu P, Johnston S. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med Chem Lett. 2012 Apr 9;3(5):416-21. doi: 10.1021/ml300049d. eCollection 2012 May 10. PubMed PMID: 24900486; PubMed Central PMCID: PMC4025802.
4: Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, Yu P, Li C, Del Rosario G, Choo EF, Hoeflich KP, Shi Y, Aftab BT, Aoyama R, Lam ST, Belvin M, Prescott J. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012 Jun 1;18(11):3090-9. doi: 10.1158/1078-0432.CCR-12-0445. Epub 2012 Apr 10. PubMed PMID: 22496205.
5: Choo EF, Belvin M, Boggs J, Deng Y, Hoeflich KP, Ly J, Merchant M, Orr C, Plise E, Robarge K, Martini JF, Kassees R, Aoyama RG, Ramaiya A, Johnston SH. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metab Dispos.

NMR, HPLC 99%, LCMS, Empagliflozin, CAS: 864070-44-0, 1.5KG in stock, Pls check:

NMR, HPLC 99%, LCMS,COA,Empagliflozin, CAS: 864070-44-0, Pls kindly check:

Description: Empagliflozin, also known as BI10773 (trade name Jardiance), is drug approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be absorbed by the kidneys and eliminated in urine. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood.

Name: Empagliflozin 

CAS#: 864070-44-0 

Chemical Formula: C23H27ClO7 

Exact Mass: 450.14453 

Molecular Weight: 450.91 

Elemental Analysis: C, 61.26; H, 6.04; Cl, 7.86; O, 24.84

Synonym: BI10773; BI-10773; BI 10773; CE0108; CS0940; PB23119; VA10802; AJ93046; Empagliflozin; trade name Jardiance.

IUPAC/Chemical Name: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

InChi Key: OBWASQILIWPZMG-QZMOQZSNSA-N

InChi Code: InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1

TECHNICAL DATA

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

2017 China CPHI: E1M35

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

労働時間: Beijing Time 4:00AM~11:00PM

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Skype: willgutian

QQ: 2393923585

1: Heise T, Mattheus M, Woerle HJ, Broedl UC, Macha S. Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study. Clin Ther. 2015 Jan 27. pii: S0149-2918(14)00879-0. doi: 10.1016/j.clinthera.2014.12.018. [Epub ahead of print] PubMed PMID: 25636696.

2: Nishimura R, Tanaka Y, Koiwai K, Inoue K, Hach T, Salsali A, Lund SS, Broedl UC. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015 Jan 30;14(1):11. [Epub ahead of print] PubMed PMID: 25633683.

3: Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes. Diabetes Care. 2015 Jan 29. pii: dc142365. [Epub ahead of print] PubMed PMID: 25633662.

4: Kvapil M. [Empagliflozin: another of silent revolutioners]. Vnitr Lek. 2014 Nov;60(11):924-5. Czech. PubMed PMID: 25612346.

5: Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Horm Metab Res. 2015 Jan 22. [Epub ahead of print] PubMed PMID: 25611208.

6: Rušavý Z. [New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes]. Vnitr Lek. 2014 Nov;60(11):926-7, 929-30. Czech. PubMed PMID: 25600037.

7: DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care. 2015 Jan 12. pii: dc142364. 

Olodaterol (868049-49-4) API and Intermediates, NMR, HPLC 99.2%, LCMS, Pls check:

Olodaterol (868049-49-4) API and Intermediates, we are China biggest GMP / ISO supplier.

Until 2017 July, we have more than 10kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok, pls kindly check:

Olodaterol Intermediate: CAS 869477-96-3; HPLC 99.2%, now COA, NMR, HPLC, MS is ok.

 

Olodaterol Intermediate: 6-benzyloxy-8-((R)-2-chloro-1-hydroxy-ethyl)-4H-benzo[1,4]-oxazin-3-one

CAS 869478-11-5; HPLC 99%, now COA, NMR, HPLC, MS is ok.

 

Olodaterol Intermediate: 8-(2R)-Oxiranyl-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one

CAS 869478-12-6; HPLC 99.2%. now COA, NMR, HPLC, MS is ok.

Olodaterol Intermediate CAS 869478-09-1; Until 2017 July, HPLC 99.2%, now COA, NMR, HPLC, MS is ok.

Olodaterol Intermediate CAS 56490-94-9; HPLC 99%, now COA, NMR, HPLC, MS is ok.

Olodaterol Intermediate:1,1-dimethyl-2-(4-methoxyphenyl)ethylamine hydrochloride

 CAS 56490-93-8; HPLC99%, now COA, NMR, HPLC, MS is ok.

2017 China CPHI: E1M35

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

労働時間: Beijing Time 4:00AM~11:00PM

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Skype: willgutian

QQ: 2393923585

Biggest Manufacturer ABT-530 [1353900-92-1] and Intermediates

ABT-530 [1353900-92-1]

Name: Pibrentasvir 
CAS#: 1353900-92-1 
Chemical Formula: C57H65F5N10O8

NMR, HPLC 99%+, LCMS, Stock more than 20G, pls kindly check:

ABT-530 Intermediate [CAS: 1890114-11-0],NMR, HPLC99%+, LCMS, COA, stock more than 1kg.

ABT-530 Intermediate [CAS: 1332357-14-8],NMR, HPLC99%+, LCMS, COA, stock more than 1kg.

ABT-530 Intermediate [CAS: 1292836-20-4],NMR, HPLC99%+, LCMS, COA, stock more than 1kg.

ABT-530 Intermediate [CAS: 1332356-31-6],NMR, HPLC99%+, LCMS, COA, stock more than 1kg.

Name:(2S,2'S)-2,2'-[[(2R,5R)-1-[3,5-Difluoro-4-[4-(4-fluorophenyl)-1-piperidinyl]phenyl]-2,5-pyrrolidinediyl]bis(6-fluoro-1H-benzimidazole-5,2-diyl)]bis-1-pyrrolidinecarboxylic acid 1,1'-bis(1,1-dimethylethyl) ester

CAS: 1890114-11-0, 

Molecular Formula: C53H59F5N8O4

Molecular Weight: 967.08

CAS Registry Number: 1890114-11-0


Description: Pibrentasvir, also known as ABT-530, is a protease inhibitor potentially for the treatment of HCV infection.

Name: Pibrentasvir  abt-530

CAS#: 1353900-92-1 

Chemical Formula: C57H65F5N10O8 

Exact Mass: 1112.4907 

Molecular Weight: 1113.2 

Elemental Analysis: C, 61.50; H, 5.89; F, 8.53; N, 12.58; O, 11.50

TECHNICAL DATA

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code: 293490

REFERENCES

1: Hussar DA, Inman B. Betrixaban, sofosbuvir/velpatasvir/voxilaprevir, and glecaprevir/pibrentasvir. J Am Pharm Assoc (2003). 2017 Nov - Dec;57(6):750-754. doi: 10.1016/j.japh.2017.10.002. PubMed PMID: 29092766.

2: Kaufman MB. Pharmaceutical Approval Update. P T. 2017 Nov;42(11):673-683. PubMed PMID: 29089721; PubMed Central PMCID: PMC5642154.

3: Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 2017 Oct 20. doi: 10.1007/s00535-017-1396-0. [Epub ahead of print] PubMed PMID: 29052790.

4: Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Collins C, Lei Y, Kosloski M, Mensa FJ. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017 Oct 12;377(15):1448-1455. doi: 10.1056/NEJMoa1704053. PubMed PMID: 29020583.

5: Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2017 Sep 22. pii: S1542-3565(17)31162-X. doi: 10.1016/j.cgh.2017.09.027. [Epub ahead of print] PubMed PMID: 28951228.

6: Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T, Naganuma A, Watanabe T, Eguchi Y, Yoshiji H, Seike M, Takei Y, Kato K, Alves K, Burroughs M, Redman R, Pugatch DL, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Kumada H. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391-5. [Epub ahead of print] PubMed PMID: 28948366.

7: Lamb YN. Glecaprevir/Pibrentasvir: First Global Approval. Drugs. 2017 Oct;77(16):1797-1804. doi: 10.1007/s40265-017-0817-y. PubMed PMID: 28929412.

8: Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial. Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541. [Epub ahead of print] PubMed PMID: 28926120.

9: Davis MI, Chute DF, Chung RT, Sise ME. When and how can nephrologists treat hepatitis C virus infection in dialysis patients? Semin Dial. 2017 Sep 18. doi: 10.1111/sdi.12650. [Epub ahead of print] Review. PubMed PMID: 28925068.

10: Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H. Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection. Hepatology. 2017 Sep 2. doi: 10.1002/hep.29510. [Epub ahead of print] PubMed PMID: 28865152.

11: Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. Epub 2017 Aug 14. PubMed PMID: 28818546.

12: Kosloski MP, Zhao W, Asatryan A, Kort J, Geoffroy P, Liu W. No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir. Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00958-17. doi: 10.1128/AAC.00958-17. Print 2017 Oct. PubMed PMID: 28807904; PubMed Central PMCID: PMC5610490.

13: Lin CW, Dutta S, Ding B, Wang T, Zadeikis N, Asatryan A, Kort J, Campbell A, Podsadecki T, Liu W. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects. J Clin Pharmacol. 2017 Dec;57(12):1616-1624. doi: 10.1002/jcph.959. Epub 2017 Aug 11. PubMed PMID: 28800195.

14: Lin CW, Dutta S, Zhao W, Asatryan A, Campbell A, Liu W. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2017 Jul 7. doi: 10.1007/s13318-017-0428-8. [Epub ahead of print] PubMed PMID: 28688001.

15: Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Peña JM, Arias A, Barreiro P. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother. 2017 Aug;18(12):1235-1242. doi: 10.1080/14656566.2017.1346609. Epub 2017 Jul 30. Review. PubMed PMID: 28644739.

16: Molino S, Martin MT. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility. Ann Pharmacother. 2017 Sep;51(9):811-816. doi: 10.1177/1060028017704857. Epub 2017 May 6. PubMed PMID: 28480743.

17: Lin CW, Dutta S, Asatryan A, Wang H, Clifton J 2nd, Campbell A, Liu W. Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study. Clin Pharmacol Drug Dev. 2017 May 2. doi: 10.1002/cpdd.350. [Epub ahead of print] PubMed PMID: 28464496.

18: Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 Aug;67(2):263-271. doi: 10.1016/j.jhep.2017.03.039. Epub 2017 Apr 13. PubMed PMID: 28412293.

19: Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02558-16. doi: 10.1128/AAC.02558-16. Print 2017 May. PubMed PMID: 28193664; PubMed Central PMCID: PMC5404558.

20: Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017 Aug;66(2):389-397. doi: 10.1002/hep.29081. Epub 2017 Apr 10. PubMed PMID: 28128852; PubMed Central PMCID: PMC5573922.

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

労働時間: Beijing Time 4:00AM~11:00PM

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Skype: willgutian

QQ: 2393923585